Please wait while the formulary information is being retrieved.
Drug overview for CYRAMZA (ramucirumab):
Generic name: RAMUCIRUMAB (RA-mue-SIR-ue-mab)
Drug class: Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody
Therapeutic class: Antineoplastics
Ramucirumab, a recombinant human IgG1 monoclonal antibody, is a vascular endothelial growth factor receptor (VEGFR)-2 antagonist.
No enhanced Uses information available for this drug.
Generic name: RAMUCIRUMAB (RA-mue-SIR-ue-mab)
Drug class: Vascular Endothelial Growth Factor(VEGF) Monoclonal Antibody
Therapeutic class: Antineoplastics
Ramucirumab, a recombinant human IgG1 monoclonal antibody, is a vascular endothelial growth factor receptor (VEGFR)-2 antagonist.
No enhanced Uses information available for this drug.
DRUG IMAGES
CYRAMZA 500 MG/50 ML VIAL
CYRAMZA 100 MG/10 ML VIAL
The following indications for CYRAMZA (ramucirumab) have been approved by the FDA:
Indications:
Gastric cancer
Liver cell carcinoma
Metastatic colorectal cancer
Metastatic non-small cell lung cancer with EGFR exon 19 deletion
Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation
Non-small cell lung cancer
Professional Synonyms:
EGFR exon 19 deletion mutation-positive metastatic non-small cell lung cancer (NSCLC)
EGFR L858R substitution mutation-positive metastatic non-small cell lung cancer (NSCLC)
Gastric malignancy
Hepatocarcinoma
Hepatocellular carcinoma
Malignant neoplasm of stomach
Malignant tumor of stomach
Metastatic non-small cell lung cancer with EGFR exon 21 Leu858Arg substitution
Metastatic NSCLC with EGFR Ex19Del
Indications:
Gastric cancer
Liver cell carcinoma
Metastatic colorectal cancer
Metastatic non-small cell lung cancer with EGFR exon 19 deletion
Metastatic non-small cell lung cancer with EGFR exon 21 L858R substitution mutation
Non-small cell lung cancer
Professional Synonyms:
EGFR exon 19 deletion mutation-positive metastatic non-small cell lung cancer (NSCLC)
EGFR L858R substitution mutation-positive metastatic non-small cell lung cancer (NSCLC)
Gastric malignancy
Hepatocarcinoma
Hepatocellular carcinoma
Malignant neoplasm of stomach
Malignant tumor of stomach
Metastatic non-small cell lung cancer with EGFR exon 21 Leu858Arg substitution
Metastatic NSCLC with EGFR Ex19Del
The following dosing information is available for CYRAMZA (ramucirumab):
If toxicities occur, temporary or permanent discontinuance of ramucirumab may be required based on causality.
Ramucirumab should be permanently discontinued in patients who develop severe (grade 3 or 4) bleeding, arterial thromboembolic events, clinically important hypertension that is not controlled with antihypertensive therapy, hypertensive crisis, hypertensive encephalopathy, grade 3 or 4 infusion-related effects, GI perforation, nephrotic syndrome, proteinuria exceeding 3 g per 24 hours, or reversible posterior leukoencephalopathy syndrome (RPLS). (See Cautions: Warnings/Precautions.)
Ramucirumab therapy should be temporarily suspended prior to surgery or if wound healing complications develop during therapy. Therapy also should be temporarily interrupted in patients who develop severe hypertension or proteinuria. (See Hypertension and also Proteinuria under Dosage: Dosage Modification for Toxicity, in Dosage and Administration.)
Ramucirumab should be permanently discontinued in patients who develop severe (grade 3 or 4) bleeding, arterial thromboembolic events, clinically important hypertension that is not controlled with antihypertensive therapy, hypertensive crisis, hypertensive encephalopathy, grade 3 or 4 infusion-related effects, GI perforation, nephrotic syndrome, proteinuria exceeding 3 g per 24 hours, or reversible posterior leukoencephalopathy syndrome (RPLS). (See Cautions: Warnings/Precautions.)
Ramucirumab therapy should be temporarily suspended prior to surgery or if wound healing complications develop during therapy. Therapy also should be temporarily interrupted in patients who develop severe hypertension or proteinuria. (See Hypertension and also Proteinuria under Dosage: Dosage Modification for Toxicity, in Dosage and Administration.)
Ramucirumab is administered by IV infusion over 1 hour. The drug should not be administered by rapid IV injection, such as IV ''push'' or ''bolus.'' Ramucirumab injection concentrate must be diluted prior to administration.
Diluted ramucirumab solution should be inspected visually for particulate matter and discoloration prior to administration; if particulate matter or discoloration is evident, the diluted solution should be discarded. Diluted ramucirumab solution should be administered using an infusion pump. The manufacturer recommends administering the drug through a low-protein-binding 0.22-mcm
inline filter. Diluted ramucirumab solution should not be administered in the same IV line with any other drug or electrolyte solution. The IV line should be flushed with 0.9%
sodium chloride injection at the end of the infusion. Unopened vials of ramucirumab injection concentrate should be protected from light, stored at 2-8degreesC, and should not be frozen or shaken.
Diluted ramucirumab solution should be inspected visually for particulate matter and discoloration prior to administration; if particulate matter or discoloration is evident, the diluted solution should be discarded. Diluted ramucirumab solution should be administered using an infusion pump. The manufacturer recommends administering the drug through a low-protein-binding 0.22-mcm
inline filter. Diluted ramucirumab solution should not be administered in the same IV line with any other drug or electrolyte solution. The IV line should be flushed with 0.9%
sodium chloride injection at the end of the infusion. Unopened vials of ramucirumab injection concentrate should be protected from light, stored at 2-8degreesC, and should not be frozen or shaken.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| CYRAMZA 100 MG/10 ML VIAL | Maintenance | Adults infuse 8 mg/kg over 60 minute(s) by intravenous route every 2 weeks |
| CYRAMZA 500 MG/50 ML VIAL | Maintenance | Adults infuse 8 mg/kg over 60 minute(s) by intravenous route every 2 weeks |
No generic dosing information available.
The following drug interaction information is available for CYRAMZA (ramucirumab):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Sodium Iodide I 131/Myelosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sodium iodide I 131 can cause depression of the hematopoetic system. Myelosuppressives and immunomodulators also suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of sodium iodide I 131 with agents that cause bone marrow depression, including myelosuppressives or immunomodulators, may result in an enhanced risk of hematologic disorders, including anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia. Bone marrow depression may increase the risk of serious infections and bleeding.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of sodium iodide I 131 states that concurrent use with bone marrow depressants may enhance the depression of the hematopoetic system caused by large doses of sodium iodide I 131.(1) Sodium iodide I 131 causes a dose-dependent bone marrow suppression, including neutropenia or thrombocytopenia, in the 3 to 5 weeks following administration. Patients may be at increased risk of infections or bleeding during this time. Monitor complete blood counts within one month of therapy. If results indicate leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity.(1) DISCUSSION: Hematologic disorders including death have been reported with sodium iodide I 131. The most common hematologic disorders reported include anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia.(1) |
HICON, SODIUM IODIDE I-131 |
There are 0 moderate interactions.
The following contraindication information is available for CYRAMZA (ramucirumab):
Drug contraindication overview.
The manufacturer states there are no known contraindications to the use of ramucirumab.
The manufacturer states there are no known contraindications to the use of ramucirumab.
There are 7 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Acute myocardial infarction |
| Acute thromboembolic stroke |
| Gastrointestinal hemorrhage |
| Gastrointestinal perforation |
| Hemorrhage |
| Lactation |
| Posterior reversible encephalopathy syndrome |
There are 11 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Acute arterial thromboembolism |
| Child-pugh class A hepatic impairment |
| Child-pugh class B hepatic impairment |
| Child-pugh class C hepatic impairment |
| Hepatic cirrhosis |
| Hypertension |
| Impaired wound healing |
| Invasive surgical procedure |
| Pregnancy |
| Proteinuria |
| Transient cerebral ischemia |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypothyroidism |
The following adverse reaction information is available for CYRAMZA (ramucirumab):
Adverse reaction overview.
Adverse effects reported in 5% or more of patients with advanced or metastatic gastric adenocarcinoma receiving ramucirumab as a single agent in the REGARD study and occurring at an incidence at least 2% higher than that reported with placebo include hypertension, diarrhea, bleeding or hemorrhage, headache, proteinuria, and hyponatremia. Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab as a single agent in the REGARD study include neutropenia, epistaxis, rash, anemia, intestinal obstruction, arterial thromboembolic events, GI perforation, and infusion-related reactions. Adverse effects reported in 5% or more of patients with advanced or metastatic gastric adenocarcinoma receiving ramucirumab in combination with paclitaxel in the RAINBOW study and occurring at an incidence at least 2% higher than that reported with placebo plus paclitaxel include fatigue or asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, hypertension, stomatitis, proteinuria, thrombocytopenia, hypoalbuminemia, and GI hemorrhage.
Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab in combination with paclitaxel in the RAINBOW study include sepsis and GI perforation. Adverse effects reported in 5% or more of patients with metastatic NSCLC receiving ramucirumab in combination with docetaxel in the REVEL study and occurring at an incidence at least 2% higher than that reported with placebo plus docetaxel include neutropenia, fatigue or asthenia, stomatitis or mucosal inflammation, epistaxis, febrile neutropenia, peripheral edema, thrombocytopenia, increased lacrimation, hypertension, diarrhea, decreased appetite, neuropathy, leukopenia, pyrexia, myalgia, arthralgia, back pain, dysgeusia, and insomnia. Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab in combination with docetaxel in the REVEL study include hyponatremia and proteinuria.
Adverse effects reported in the RAISE study in 5% or more of patients with metastatic colorectal cancer receiving ramucirumab in combination with FOLFIRI and at an incidence at least 2% higher than that reported with placebo plus FOLFIRI include diarrhea, neutropenia, fatigue, hemorrhage, decreased appetite, epistaxis, stomatitis, vomiting, constipation, abdominal pain, thrombocytopenia, hypertension, peripheral edema, mucosal inflammation, proteinuria, pyrexia, headache, decreased weight, cough, liver injury or liver failure, palmar-plantar erythrodysesthesia (hand-foot syndrome), GI hemorrhage, venous thromboembolic event, hypoalbuminemia, and infusion-related reactions. Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab in combination with FOLFIRI include GI perforation.
Adverse effects reported in 5% or more of patients with advanced or metastatic gastric adenocarcinoma receiving ramucirumab as a single agent in the REGARD study and occurring at an incidence at least 2% higher than that reported with placebo include hypertension, diarrhea, bleeding or hemorrhage, headache, proteinuria, and hyponatremia. Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab as a single agent in the REGARD study include neutropenia, epistaxis, rash, anemia, intestinal obstruction, arterial thromboembolic events, GI perforation, and infusion-related reactions. Adverse effects reported in 5% or more of patients with advanced or metastatic gastric adenocarcinoma receiving ramucirumab in combination with paclitaxel in the RAINBOW study and occurring at an incidence at least 2% higher than that reported with placebo plus paclitaxel include fatigue or asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, hypertension, stomatitis, proteinuria, thrombocytopenia, hypoalbuminemia, and GI hemorrhage.
Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab in combination with paclitaxel in the RAINBOW study include sepsis and GI perforation. Adverse effects reported in 5% or more of patients with metastatic NSCLC receiving ramucirumab in combination with docetaxel in the REVEL study and occurring at an incidence at least 2% higher than that reported with placebo plus docetaxel include neutropenia, fatigue or asthenia, stomatitis or mucosal inflammation, epistaxis, febrile neutropenia, peripheral edema, thrombocytopenia, increased lacrimation, hypertension, diarrhea, decreased appetite, neuropathy, leukopenia, pyrexia, myalgia, arthralgia, back pain, dysgeusia, and insomnia. Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab in combination with docetaxel in the REVEL study include hyponatremia and proteinuria.
Adverse effects reported in the RAISE study in 5% or more of patients with metastatic colorectal cancer receiving ramucirumab in combination with FOLFIRI and at an incidence at least 2% higher than that reported with placebo plus FOLFIRI include diarrhea, neutropenia, fatigue, hemorrhage, decreased appetite, epistaxis, stomatitis, vomiting, constipation, abdominal pain, thrombocytopenia, hypertension, peripheral edema, mucosal inflammation, proteinuria, pyrexia, headache, decreased weight, cough, liver injury or liver failure, palmar-plantar erythrodysesthesia (hand-foot syndrome), GI hemorrhage, venous thromboembolic event, hypoalbuminemia, and infusion-related reactions. Clinically important adverse effects reported in less than 5% of patients receiving ramucirumab in combination with FOLFIRI include GI perforation.
There are 24 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Hypertension Neutropenic disorder Palmar-plantar erythrodysesthesia Proteinuria |
Acute arterial thromboembolism Gastrointestinal obstruction Hypoalbuminemia Hyponatremia Hypothyroidism Thrombocytopenic disorder |
| Rare/Very Rare |
|---|
|
Arterial aneurysm Arterial dissection Bronchospastic pulmonary disease Gastrointestinal hemorrhage Gastrointestinal perforation Heart failure Hemangioma Hemorrhage Hypotension Impaired wound healing Nephrotic syndrome Posterior reversible encephalopathy syndrome Supraventricular tachycardia Thrombotic thrombocytopenic purpura |
There are 23 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Diarrhea Epistaxis Fatigue Headache disorder Stomatitis |
Acute abdominal pain Anorexia Eye tearing Fever Nausea Peripheral edema Skin rash Vomiting |
| Rare/Very Rare |
|---|
|
Back pain Chest pain Chills Dyspnea Flushing Hypoxia Paresthesia Tremor Voice change Wheezing |
The following precautions are available for CYRAMZA (ramucirumab):
Safety and efficacy of ramucirumab have not been established in pediatric patients younger than 18 years of age. In animals, exposure to ramucirumab at concentrations 0.2 times that of human clinical exposure resulted in toxicities in bone (i.e., thickening of epiphyseal growth plates, osteochondropathy).
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Based on its mechanism of action, ramucirumab may cause fetal harm if administered to pregnant women. (See Fetal/Neonatal Morbidity and Mortality under Cautions: Warnings/Precautions.)
It is not known whether ramucirumab is distributed into human milk. Human immunoglobulin G (IgG) is distributed into milk; however, published data suggest that antibodies contained in breast milk do not enter the neonatal and infant circulation in substantial amounts. Nevertheless, because of the potential for serious adverse reactions to ramucirumab in nursing infants, the manufacturer states that nursing during ramucirumab therapy is not recommended. Data are lacking on the effects of the drug in nursing infants or on the production of milk.
In the REGARD and RAINBOW studies, 36% of patients with advanced or metastatic gastric adenocarcinoma receiving ramucirumab were 65 years of age or older, and 7% were 75 years of age or older. No overall differences in safety or efficacy were observed between geriatric and younger adults. In the REVEL study, 36% of patients with metastatic NSCLC receiving ramucirumab in combination with docetaxel were 65 years of age or older, and 7% were 75 years of age or older.
In an exploratory subgroup analysis, survival benefit was not observed in patients 65 years of age or older receiving ramucirumab in combination with docetaxel (hazard ratio 1.10). In the RAISE study, 40% of patients with metastatic colorectal cancer receiving ramucirumab in combination with FOLFIRI were 65 years of age or older, and 10% were 75 years of age or older. No overall differences in safety or efficacy were observed between geriatric and younger adults in this study.
In an exploratory subgroup analysis, survival benefit was not observed in patients 65 years of age or older receiving ramucirumab in combination with docetaxel (hazard ratio 1.10). In the RAISE study, 40% of patients with metastatic colorectal cancer receiving ramucirumab in combination with FOLFIRI were 65 years of age or older, and 10% were 75 years of age or older. No overall differences in safety or efficacy were observed between geriatric and younger adults in this study.
The following prioritized warning is available for CYRAMZA (ramucirumab):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CYRAMZA (ramucirumab)'s list of indications:
| Gastric cancer | |
| C16 | Malignant neoplasm of stomach |
| C16.0 | Malignant neoplasm of cardia |
| C16.1 | Malignant neoplasm of fundus of stomach |
| C16.2 | Malignant neoplasm of body of stomach |
| C16.3 | Malignant neoplasm of pyloric antrum |
| C16.4 | Malignant neoplasm of pylorus |
| C16.5 | Malignant neoplasm of lesser curvature of stomach, unspecified |
| C16.6 | Malignant neoplasm of greater curvature of stomach, unspecified |
| C16.8 | Malignant neoplasm of overlapping sites of stomach |
| C16.9 | Malignant neoplasm of stomach, unspecified |
| Liver cell carcinoma | |
| C22.0 | Liver cell carcinoma |
| Metastatic colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| Metastatic NSCLC with EGFR exon 19 deletion | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| Metastatic NSCLC with EGFR exon 21 l858R substitution | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| Non-small cell lung cancer | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
Formulary Reference Tool